July 26, 2010: Aurgalys & CLS issue a new BioAlliance analyst note : Acyclovir Lauriad® to be registered in EU – Record turnover for S1 2010
juillet 26, 2010
Aurgalys issued today July26th, 2010, an new analyst report on BioAlliance.
- Acyclovir Lauriad®: the Company has engaged discussion with European regulatory agencies and obtained a registration slot
- S1 2010 record turnover: €21.3 M versus €4.1 M for the same period in 2009
Since our coverage initiated on June 19th, 2009, the stock increased 61% from €3.44 to €5.53 today.
Download our BioAlliance Analyst Report here (available in english only)